CAGE Bio, TAGCyx, and PeptiStar Announce Execution of a License Agreement for Develop

  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us
  • More
    • Home
    • About Us
      • Board of Directors
      • Scientific Advisory Board
      • Business Advisors
      • Partnerships
    • Our Technology
    • People
      • Our Team
      • Career
    • Patients
      • Clinical Trials
    • Media
      • Press Releases
      • In the news
      • Publications
    • Contact Us
  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us

Press Releases

SEPTEMBER 15, 2022

CAGE Bio, TAGCyx, and PeptiStar Announce License Agreement for Dev & Comm. of TAGX-0003

San Carlos, CA; Fort Worth, TX

Event Details

SEPTEMBER 15, 2022

CAGE Bio, TAGCyx, and PeptiStar Announce License Agreement for Dev & Comm. of TAGX-0003

CAGE Bio Inc., announced the execution of a license agreement for development of TAGX-0003 for the targeted treatment of alopecia areata and...

Event Details

San Carlos, CA; Fort Worth, TX

May 11, 2021

CAGE Bio Initiates Phase 2 Study for Treatment of Rosacea

San Carlos, CA; Fort Worth, TX

Event Details

May 11, 2021

CAGE Bio Initiates Phase 2 Study for Treatment of Rosacea

CAGE Bio Inc., announced dosing of the first patient in its Phase 2 clinical trial for the treatment of inflammatory lesions of rosacea. The...

Event Details

San Carlos, CA; Fort Worth, TX

February 16, 2021

CAGE Bio Closes $7.2 Million Round of Series A Funding

San Carlos, CA; Fort Worth, TX

Event Details

February 16, 2021

CAGE Bio Closes $7.2 Million Round of Series A Funding

CAGE Bio Inc., announced the closing of a $7.2 million over-subscribed Series A financing.  The investment was led by professional and angel...

Event Details

San Carlos, CA; Fort Worth, TX

September 18, 2020

TAGCyx announces a research collaboration with CAGE Bio Inc. for autoimmune skin diseases

San Carlos, CA; Fort Worth, TX

Event Details

September 18, 2020

TAGCyx announces a research collaboration with CAGE Bio Inc. for autoimmune skin diseases

  1. TAGCyx biotechnologies Inc. announced entering into a research collaboration with CAGE Bio Inc. for development of TAGX-0003 for treatment o...

Event Details

San Carlos, CA; Fort Worth, TX

July 23, 2020

Biotech Startup Discovers Novel Hand Sanitizer for COVID-19, Offering Long-Lasting 4+ hrs of protect

San Carlos, CA; Fort Worth, TX

Event Details

July 23, 2020

Biotech Startup Discovers Novel Hand Sanitizer for COVID-19, Offering Long-Lasting 4+ hrs of protect

CAGE Bio Inc., today announced discovery of a novel hand sanitizer that offers long-lasting protection from coronavirus and other harmful vi...

Event Details

San Carlos, CA; Fort Worth, TX

More Events

Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Welcome! Check out our latest news.

CAGE Bio, TAGCyx, and PeptiStar Announce Execution of a License Agreement for Development and Commercialization of TAGX-0003 for the Treatment of Immunodermatology Diseases Mediated by the IFN-Gamma Pathway

Learn more